Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 9/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18430943 | 1.00 | TSHR (0.42) | TSHRTHRBEPHX1GGPS1LPAR3 | |
| SCHEMBL13181419 | 1.00 | TSHR (0.42) | TSHRTHRBEPHX1GGPS1LPAR3 | |
| SCHEMBL20413846 | 1.00 | TSHR (0.42) | TSHRTHRBEPHX1GGPS1LPAR3 | |
| SCHEMBL22624028 | 1.00 | TSHR (0.42) | TSHRTHRBEPHX1GGPS1LPAR3 | |
| SCHEMBL13181417 | 0.97 | TSHR (0.40) | TSHRTHRBEPHX1GGPS1LPAR3 | |
| SCHEMBL24533765 | 0.90 | EPHX1 (0.39) | TSHRTHRBEPHX1GGPS1LPAR3 | |
| SCHEMBL29107041 | 0.89 | TSHR (0.33) | TSHRTHRBEPHX1FDPS | |
| SCHEMBL20930917 | 0.87 | EPHX1 (0.35) | TSHRTHRBEPHX1GGPS1LPAR3 | |
| SCHEMBL19645598 | 0.84 | ALDH1A1 (0.31) | TSHREPHX1 | |
| SCHEMBL20716197 | 0.79 | TSHR (0.42) | TSHRTHRBEPHX1GGPS1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | TSHR 4461/4885THRB 1733/4885EPHX1 1313/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | TSHR 4461/4885THRB 1733/4885EPHX1 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.